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ABSTRACT
Due to its tendency to recur and acquire chemoresistance quickly, bladder
cancer (BC) remains to be an elusive and difficult disease. Patients with recurrent
and chemoresistant BC have an extremely poor prognosis. One possible approach that
may provide insightful and valuable information regarding resistance mechanisms
is looking into the lipid metabolism of BC cells. Metabolism of lipids is essential
for cancer cells and is associated with the regulation of a variety of key cellular
processes and functions. This study conducted a comparative lipidomic profiling
of two isogenic human T24 bladder cancer cell lines, one of which is clinically
characterized as cisplatin-sensitive (T24S) and the other as cisplatin-resistant (T24R).
Immunohistochemistry analysis revealed that expression of cytosolic acetyl-CoA
synthetase 2 (ACSS2) is positively correlated with aggressive BC. Ultra performance
liquid chromatography-mass spectrometry (UPLC-MS) analysis profiled a total of 1,864
lipids and levels of differentially expressed lipids suspected of being associated with
cisplatin resistance were determined. In addition, we found that ACSS2 inhibition
greatly perturbed levels of metabolites, including CE(18:1), CE(22:6), TG(49:1), and
TG(53:2). This study broadens our current knowledge on the links between cisplatin
resistance and lipid metabolism in aggressive BC and suggests potential biomarkers
for identifying higher-risk patients.

INTRODUCTION

builds up quickly, leaving fewer options for treatment. The
mechanisms driving this increased resistance to cisplatin
over time are generally unknown.
Since cancer initiation and progression is associated
with changes in metabolism, investigation into the
metabolomics of cancer could prove to be useful. In
particular, dysregulated lipid metabolism, which regulates
diverse classes of molecules that play critical roles in cellular
energy, storage, and signaling [6], has been associated with
aggressive forms of different cancers [7–10]. Furthermore,
given that lipid metabolism is regulated by several oncogenic

Bladder cancer (BC) has undoubtedly impacted the
lives of many, as it has become the ﬁfth most prevalent
type of cancer, with ~76,000 new cases and ~16,300 deaths
per year worldwide [1–4]. Albeit treatment varies with
each patient and tumor stage when found, the standard of
treatment for BC usually involves surgical resection of the
tumor followed by adjuvant chemotherapy with cisplatin
[5]. While effective in some forms of cancer, cisplatin
often loses its efﬁcacy in BC patients. Resistance often
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signaling pathways and is important for the initiation and
progression of tumors [11], it is widely accepted that lipid
alterations may serve as potential cancer biomarkers [12].
Lipidomic analysis aims to identify and quantify all the
relevant lipids along with the goal of characterizing their
interactions with other cellular components and functions,
such as proteins or gene expression [13, 14]. Lipid and
phospholipid metabolism also plays key roles in cellular
motility, cell invasion, and tumor metastasis. Previous reports
have shown that metabolic perturbation of phospholipids is
associated with various cancer types [5, 15, 16], indicating
that the composition of phospholipids may be critical for
deciding the fate of tumor cells.
In this study, we hypothesized that a perturbed
phospholipid metabolism is implicated in the more
aggressive variants of BC. We sought to determine the
lipid alterations underlying cisplatin resistance and address
the lack of knowledge between metabolite alterations
and drug resistance. Through a state-of-the-art mass
spectrometry approach, the experimental results identiﬁed
lipid metabolites speciﬁc to cisplatin-resistant BC cells.

microarrays using a commercially available ACSS2 antibody
(Figure 1C–1D). This experiment revealed elevated ACSS2
expression in bladder tumor tissue cores. Our IHC analysis
further conﬁrmed that ACSS2 is more abundantly expressed
in tumor samples of higher grades. These experimental results
suggest that ACSS2 expression is signiﬁcantly increased in
BC cells and may also positively correlate with tumor grade.
Recently, high-throughput small molecule
screenings of over 200,000 chemical compounds have
identiﬁed inhibitors of ACSS2. One of the most potent and
speciﬁc inhibitors is 1-(2,3-di(thiophen-2-yl)quinoxalin-6yl)-3-(2-methoxyethyl)urea [25–27]. We were curious to
see if inhibition of ACSS2 would have any effect on BC
cells. We treated a set of normal bladder and BC cell lines
(TRT-HU1, RT4, 5367, T24, and TCCSUP) with ACSS2
inhibitor for 24 h. Using this small ACSS2-inhibitory
compound (MolPort), we found that total lipid levels of
BC cell lines decreased, whereas those of normal cells
(TRT-HU1) were not affected (Figure 1E).

Identiﬁcation of the lipids associated with
cisplatin resistance

RESULTS

In order to determine the lipidomics proﬁle of cisplatinresistant BC cells, global and unbiased metabolomics analysis
was performed. We identiﬁed differentially expressed lipids
(DELs) by comparing BC cell lines T24R and T24S cells.
Ultra performance liquid chromatography-mass spectrometry
(UPLC-MS) detected a total of 1,864 lipids in both the
positive and negative modes. The mass-to-charge (m/z)
values, retention times, and abundance of the lipids are
shown in Supplementary Table 1.
We measured 1,037 and 827 unique lipid species
in the positive and negative modes, respectively. In the
positive mode, 127 lipid species from cholesteryl ester
(CE), ceramide (Cer), cholesterol, diacylglycerol (DG),
glucosylceramide (GlcCer), lysophosphatidylcholines (LPC),
phosphatidylcholine (PC), phosphatidylethanolamide (PE),
sphingomyelin (SM) and triglyceride (TG) were identiﬁed.
In the negative mode, 92 lipid species from Cer, fatty acyls
(FA), GlcCer, LPC, PC, PE, phosphatidylinositols (PI),
and SM were identiﬁed. Of interesting note, we found that
essential structural components of cell membranes were
major constituents of the identiﬁed lipids in both the positive
(48 PC, 11 SM, and 44 TG) and negative (14 CER, 10 FA, 32
PC, and 21 PE) modes. DELs between T24S and T24R cells
in the positive or negative ion mode are shown in Table 1 and
Supplementary Tables 2 and 3.

Characterization of isogenic cisplatin sensitiveor -resistant bladder cancer cells
To start identifying the cisplatin resistanceassociated lipid metabolome, we utilized a paired cell
culture system consisting of two isogenic cell lines,
one of which was cisplatin sensitive (T24S) and the
other resistant (T24R). Both cell lines were previously
characterized in our laboratory [17]. Compared to T24S,
T24R consistently exhibited a lower response to cisplatininduced apoptosis (Figure 1A). The total lipid levels in
T24R cells were approximately 170% of those in T24S
cells, suggested that greater lipid production may be
linked to cisplatin resistance (Figure 1B).
Prior studies have demonstrated that cancer cells
have altered lipid metabolism [18, 19]. As a carbon source
for producing fatty acids and cholesterol, acetate can
be converted into cytosolic acetyl-CoA, which plays an
important role in the TCA cycle [20–22]. The cytosolic
acetyl-CoA synthetase 2 (ACSS2) mediates increased
incorporation of acetate into lipids this processing. Given that
a signiﬁcant increase in the levels of ACSS2 has been found
in a series of cancer types, such as melanoma, breast, ovarian,
and lung cancers [21, 23–26], we speculated that ACSS2
expression may also be correlated with bladder cancer.

Inhibition of ACSS2 altered lipidomics proﬁles
in cisplatin responsive bladder cancer cells

ACSS2 expression is associated with bladder
cancer aggressiveness

We next attempted to understand the biological
effect of ACSS2 inhibition. Given our data showing that
T24 BC cells showed the biggest inhibitory effect on
lipid levels by ACSS2 inhibition, we choose T24 cells

To determine the relationship of ACSS2 to lipid
metabolism and cisplatin resistance at the molecular level,
we performed immunohistochemical (IHC) staining of tumor
www.impactjournals.com/oncotarget
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for further experiments using ACSS2 inhibitor [25–27].
The overall lipidomic proﬁles showed larger differences
between T24S and T24R cells after treatment with ACSS2
inhibitor than treatment with vehicles in both positive
(Figure 2A) and negative (Figure 2B) modes. The full list
of detected lipids in both the positive and negative modes
are shown in Supplementary Table 1.

The difference between T24S– (T24S not treated
with ACSS2 inhibitor) and T24S+ (T24S treated with
ACSS2 inhibitor) was larger compared to the difference
between T24R– (T24R not treated with ACSS2 inhibitor)
and T24R+ (T24R treated with ACSS2 inhibitor) in the
positive mode (Supplementary Table 2). The expression
patterns of DELs showed distinct abundances of various

Figure 1: Cisplatin resistance is associated with ACSS2. (A) Cisplatin resistant T24R cells showed a delayed apoptosis in response
to cisplatin treatment, compared to T24S. Cell viability was measured in the absence or presence of cisplatin media for 2 days. *p < 0.05
(Student’s t-test). (B) Total lipid levels of T24R were compared to T24S cells. **p < 0.005 (C–D) ACSS2 expression increased in bladder
cancer tissues in comparison of normal bladder tissues. (C) The BC TMA was stained with anti-ACSS2 antibody (1:100) as described in the
Materials and Methods section. The expression levels of ACSS2 were examined and quantiﬁed based on positivity of staining as previously
described. (D) Images of one representative example of staining in normal noncancerous bladder tissue (left), and one representative
example of staining in the paired bladder tumor tissues from same patients (right) were shown. (E) ACSS2 inhibition decreased total lipid
contents in a series of BC cells. Cells were incubated with ACSS2 inhibitor-containing media for 20 hrs, which was followed by lipid
measurement as described in Methods. *p < 0.05, **p < 0.005 (Student’s t-test).
www.impactjournals.com/oncotarget
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Table 1: Differentially expressed lipids (DEL) between T24S and T24R in positive or negative ion mode
Mode

Positive

Identiﬁer

Annotation

InChI Key

Species

m/z

RT

P-value

Q-value

Log2FC

Mean normalized
intensity
S-

R-

10.30_719.57

CE (22:6)

VOEVEGPMRIYYKC
-HNJOWPRISA-N

4.93_768.55

PC (35:4)

OROZWUJCDDCYAU
-IPUAOQJZSA-N

[M+H]+

768.5528

4.93

0.0204

0.0948

0.6450

18501.8

28933.0

4.47_778.54

PC (36:6)

SPWBDEZMKCRQSX
-NGPPOSSDSA-N

[M+H]+

778.5385

4.47

0.0048

0.0931

0.6402

14238.8

22192.0

5.70_724.53

PE (p-36:4)
/ PE (o-36:5)

ADWDFBQPQIEGRZ
-XBICFDGKSA-N

[M+H]+

724.5279

5.70

0.0002

0.0301

–0.6337

403765.9

260236.6

6.39_752.56

PE (p-38:4)
/ PE (o-38:5)

ZTZQZGHJLWFLFQ
-VZBWJDOASA-N

[M+H]+

752.5591

6.39

0.0142

0.0897

–0.8247

239093.0

134988.5

6.40_778.57

PE (p-40:5)
/ PE (o-40:6)

HHQFKPJXVYWLLJ
-ABYSKWQHSA-N

[M+H]+

778.5743

6.40

0.0185

0.0951

–0.6302

80510.8

52015.6

7.15_813.68
_7.15_835.67

SM (d42:2)

DACOGJMBYLZYDH
-GXJPFUDISA-N

[M+H]+
_[M+Na]+

813.6848
_835.6658

7.15

0.0070

0.0814

1.2411

204780.6

484070.9

6.56_811.66
_6.55_833.65

SM (d42:3)

TXFLWJQVQCDUDZ
-BRUGZULGSA-N

[M+H]+
_[M+Na]+

811.6624
_833.6505

6.56

0.0001

0.0558

4.3471

10492.5

213546.9

11.16_829.73
_11.17_824.77

TG (48:0)

PVNIQBQSYATKKL
-UHFFFAOYSA-N

[M+H]+
_[M+NH4]+

829.7256
_824.7705

11.17

0.0060

0.0894

–1.7587

190985.2

56439.4

11.32_838.78

TG (49:0)

TTWJTJMWHOYBPQ
-ANFMRNGASA-N

[M+NH4]+

838.7829

11.32

0.0262

0.0989

–1.6911

15051.5

4661.4

10.96_841.73
_10.96_836.77

TG (49:1)

VYYGQDOPVVYUKW
-UKFBYESTSA-N

[M+H]+
_[M+NH4]+

841.7263
_836.7709

10.96

0.0256

0.0993

–1.5552

64017.0

21784.1

11.56_857.76
_11.57_852.80

TG (50:0)

MARPCPMDFOPPJX
-UHFFFAOYSA-N

[M+Na]+
_[M+NH4]+

857.7562
_852.8018

11.57

0.0177

0.0989

–2.0145

151586.5

37517.4

11.89_885.78
_11.91_880.84

TG (52:0)

SDNYRTVJOFMYIW
-OIVUAWODSA-N

[M+H]+
_[M+NH4]+

885.784
_880.8354

11.90

0.0115

0.0920

–1.7912

96039.1

27748.3

10.69_898.79
_10.67_903.74

TG (54:5)

OEJXMJPFOHYSIU
-GRLFFVHSSA-N

[M+NH4]+
_[M+Na]+

898.7855
_903.7415

10.68

0.0191

0.0941

–1.4113

212399.1

79854.1

4.40_733.55

SM (d32:1)

KYICBZWZQPCUMO
-PSALXKTOSA-N

[M+Hac-H]-

733.5478

4.40

0.0001

0.0027

1.1264

18915.2

41295.4

7.15_871.69

SM (d42:2) B

DACOGJMBYLZYDH
-GXJPFUDISA-N

[M+Hac-H]-

871.6894

7.15

0.0012

0.0212

1.2472

46562.3

110528.3

Negative

[M+Na]+

719.5729

10.30

0.0116

0.0911

1.4461

7881.9

21476.0

Annotated DELs with q-value less than 0.1 were shown. The full list of DELs was included in Supplementary Table 2 and 3. For each DEL, unique identiﬁer given as RT, m/z,
annotation identiﬁed by MS-Dial, InChI key, formula of the lipid, m/z, retention time (RT), p-value, q-value, log2-transformed fold-change (log2FC), and mean normalized
intensities were shown.

lipid species between the cell lines and treatments in both
the positive (Figure 3A) and negative modes (Figure 2B)
(Supplementary Table 3). DEL between T24S+ and
T24S– in the negative or positive mode are shown in
Supplementary Tables 4 and 5, while those for T24R+
and T24R– in the negative or positive mode are shown in
Supplementary Tables 6 and 7.
In our heatmap constructed from the data obtained
from lipidomics analysis in the positive mode, Cluster 1
(C1) showed higher expression levels in ACSS2 inhibitor
treated cell lines, regardless of cisplatin sensitivity (Figure
2C). Cluster 2(C2) and Cluster 5(C5) showed the highest
expression in T24R– compared to others (e.g., CE (22:6)).
Cluster 3(C3) and Cluster 4(C4) showed higher expression
in T24R regardless of ACSS inhibitor treatment (e.g.,
Ceramide (d42:2), PC(36:6), PC(35:4), PC(40:8),
SM (d42:3), SM(d42:2), SM(d41:2), SM(d32:1), and
SM(d34:0)) (Figure 2C).
In contrast, the heatmap indicating lipidomics data
in the negative mode is shown in Figure 2D. The most
www.impactjournals.com/oncotarget

distinctive pattern was up-regulation in T24R, regardless
of treatment with ACSS2 inhibitor. Cluster 2 (C2) included
SM(d41:2), SM(d42:2), SM(d32:1), and PC(34:4). Cluster
1(C1) and Cluster 4(C4) showed up-regulation in ACSS
inhibitor treated cells, regardless of cisplatin sensitivity
(e.g., PC (40:6)). Cluster 3(C3) showed the lowest
expression in T24S– and the highest expression in T24R+
(e.g., Ceramide(d42:2) and Ceramide(d34:0)) (Figure 2D).

Distinct effects of ACSS2 inhibition on the lipid
metabolome in cisplatin resistant bladder cancer
cells
To further understand the metabolic consequences
of ACSS2 inhibition, the lipid metabolite proﬁles of
T24S+ and T24R+ were compared. Cisplatin-sensitive BC
cell line (T24S) showed larger changes in lipid proﬁles
compared to the resistant cell line (T24R). Among the
identiﬁed lipids, we found that 23 TG lipid species were
down-regulated in T24S+, compared to T24S–, in the
13234
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Figure 2: Differentially expressed lipids in T24R compared to T24S. (A–B) Principal component analyses (PCA) of lipid

proﬁles of T24S and T24R in the absence or presence of ACSS2 inhibitor were shown. The lipid proﬁles were acquired in (A) positive ion
mode and (B) negative ion mode. S and R indicate cisplatin sensitive and resistant bladder cancer cell lines. The positive (+) and negative
(-) symbols indicate treatment of ACSS2 inhibitor and vehicle, respectively. (C–D) Heatmaps showing differentially expressed lipids in
T24R compared to T24S in the absence and the presence of ACSS2 inhibitor treatment. (C) DELs identiﬁed in positive mode, and (D) in
negative mode.
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positive mode (Figure 3A). Four lipid species, 2 CE and 2
TG, were downregulated in T24R+, compared to T24R–,
in the positive mode (Figure 3B).
Compared to T24S in the positive mode, T24R had
42 lipid species that were upregulated and 68 species that
were downregulated. Of these lipid species, 3 PC and 5 SM
lipid species were upregulated and 3 PE and 12 TG lipid
species were downregulated (Figure 3C). Compared to
T24S+ in the positive mode, T24R + had 5 SM lipid species
that were upregulated and 3 PE and 29 TG lipid species that
were downregulated (Figure 3D).
Only a few identiﬁed lipid species were
differentially expressed between T24S+ and T24S–
(Figure 3E) and T24R+ and T24R– (Figure 3F). There
were more differentially expressed lipids associated with
cisplatin-resistance. Among the identiﬁed lipids, 6 PE
lipid species were downregulated in T24R–, compared to
T24S–, in the negative mode (Figure 3G). In addition, 2
PC and 7 PE lipid species were downregulated in T24R+,
compared to T24S+, in the negative mode (Figure 3H).
These results show that the levels of most lipid
metabolites speciﬁc to T24R were not signiﬁcantly affected
by ACSS2 inhibitor treatment (Figures 3A and 3B). Levels
of metabolites, such as CE(18:1), CE(22:6), TG(49:1), and
TG(53:2) were greatly perturbed by ACSS2 inhibition
(Figures 4A–4D). In contrast, the expression levels of
several unknown metabolites such as 11.86_1000.92,
12.22_369.35, and 8.57_711.58/8.57_735.61 decreased
only in T24R cells, but not in T24S cells (Figures 4E–4G).
Collectively, these ﬁndings suggest that cisplatin resistance
is associated with defects in acetate and lipid metabolism.

Experimental results from our study revealed a list
of identiﬁed lipids that is heterogenous and belongs to
several different classes. The original goal of this study
was to determine the global lipid metabolome in cisplatin
resistant BC. Although this is out of scope for this particular
study, there has been much speculation regarding the
potential biological signiﬁcance of differential amounts
of sphingomyelin (SM) and ceramide (CE) on membrane
structure, permeability, and signaling platform formation.
Several reports have suggested that strict distribution
patterns of lipid species and enzymes determine cell fate
through regulatory mechanisms. For instance, higher levels
of SM are associated with drug resistance, possibly through
alterations of membrane packing [31]. Sphingomyelinase,
an enzyme that catalyzes the breakdown of SM into CE
and phosphorylcholine, also induces apoptosis by altering
the balance between SM and CE. Additionally, C16:0ceramide has recently been reported as a principal mediator
of obesity-related insulin resistance [32, 33]. Furthermore,
in various cancer, phosphoglyercides, namely PC, PE,
and PI, are upregulated [34, 35]. In particular, it is known
that cholesterol and sphingolipids form speciﬁc planar
microdomains, known as lipid rafts [36]. In cancer cells,
these lipid rafts contain receptors for signaling proteins
involved in oncogenic and apoptotic pathways [37].
Cholesterol is enhanced in the cell membrane of various
cancer cells [38, 39]. Sphingolipids (sphingomyelin) are
also involved in several cancer-related processes, such as
proliferation, apoptosis and metastasis [40]. Therefore, by
compiling lipidomic data, we could identify potential lipid
signatures from a combination of different lipids, which
could then be used to classify tumor samples from healthy
controls.
Furthermore, our ﬁndings identiﬁed speciﬁc ACSS2inhibiting lipid metabolites, such as CE(18:1), CE(22:6),
TG(49:1), and TG(53:2) (Figure 4). Alterations in the
levels of phospholipid metabolites, such as PC and PE, have
often been considered as biochemical indicators of tumor
progression or drug response [41–44]. Lipid perturbation
in BC has been observed in a series of previous papers.
From 40 paired bladder cancer and adjacent normal bladder
tissues, Dill et al. found that levels of PI, PS, and FA were
changed in BC tissues [45]. Using the DESI-IMS method,
the authors found a signiﬁcant increase of PS(18:0/18:1),
PI(18:0/20:4) and FA(18:1) in bladder tumor tissues
(n = 20), compared to healthy controls (n = 20). In the dog
model BC (n = 4), levels of PS(18:0/18:1), PG(18:1/18:1),
PI(16:0/18:1), PI(18:0/18:1), PS(18:1/18:1), PC(34:1),
and PC(36:2) increased in BC tissue compared to normal
[46]. Our study demonstrates that levels of CE(22:6),
TG(49:1), and TG(53:1) et al. are signiﬁcantly elevated
in cisplatin-resistant BC cells compared to their cisplatinsensitive counterparts. This conveys that these lipids may
be actively involved in BC pathogenesis. Ceramide, a
sphingomyelin byproduct and gangliosiode precursor,
is potentially related to tumor growth and metastasis.

DISCUSSION
In this study, we sought to characterize the cisplatin
resistant lipidome in BC. Through the integration
of lipidomics and systems biology approaches, this
study has broadened our understanding of the lipid
biology associated with cisplatin resistance in BC.
The experimental results also suggest potential lipid
biomarkers and therapeutic targets.
Lipid metabolism is often disturbed in cancer cells
and this is expected to result in differing lipid composition
[28]. However, proﬁling of disease-related lipids speciﬁc
to cancer is still underdeveloped, compared to those of
genes and proteins. Lipidomics proﬁling aims to identify
lipids using mass spectrometry and annotate them based
on a metabolite database [12]. Other approaches that
allow for analysis of lipids in cancer tissue include nuclear
magnetic resonance (NMR), mass spectroscopy (MS) [12],
matrix-assisted laser desorption and ionization (MALDI),
and electrospray ionization (ESI) [29, 30], which allow
for analysis of lipids in cancer tissue. Integration of
lipidomic strategies in cancer research could generate new
opportunities to gain insights into diagnosis, prognosis and
prediction of therapies [14].
www.impactjournals.com/oncotarget
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Figure 3: Volcano plots of cisplatin sensitive and resistant bladder cancer cell lines. (A–D) Positive ion mode. (A) T24S+
and T24S–; (B) T24R+ and T24R–; (C) T24R– and T24S–; (D) T24R+ and T24S+. Cyan dots indicate the DEL (p < 0.05 and fold-change
>1.5). Magenta dots indicate the identiﬁed DEL. (E–H) Negative mode. (E) T24S+ and T24S–; (F) T24R+ and T24R–; (G) T24R– and
T24S–; (H) T24R+ and T24S+. Cyan dots indicate the DEL (p < 0.05 and fold-change >1.5). Magenta dots indicate the identiﬁed DEL.
The x-axis and y-axis show log2-tranformed fold changes and log10-transformed p-values.
www.impactjournals.com/oncotarget
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Exogenous addition of a speciﬁc ganglioside mediated the
epithelial-to-mesenchymal transition in BC cells [47], and
also inhibited cell proliferation through inhibition of the
EGFR signaling pathway [48, 49]. Furthermore, growth
of bladder tumors was delayed by GM3 in the orthotopic
bladder cancer model. N-glycolyl-GM3, which contains
N-glycolylneuraminic acid instead of N-acetylneuraminic
acid, was observed in colon and breast cancers and is
suggested as a potential target for cancer therapy. We also
found that TG species, which are composed of a glycerol
molecule linked by ester bonds to three fatty acids with
chain lengths of 49:1 or 53:2, were signiﬁcantly decreased
in cisplatin-resistant BC cells compared to cisplatin-

sensitive control cells. TG (and diacylglycerols (DG))
plays an important role in cellular membranes and signaling
pathways. TG also mediates the storage of fatty acids and
energy, and provides the precursors needed for phospholipid
biosynthesis.
Although these ﬁndings are quite exciting, this
study has several limitations. While global lipidomics
offer exciting technologies, we are aware that there are
still constraints with data interpretation. Despite the fact
that available databases for interpreting lipidomics proﬁles
have progressed rapidly in recent years, many lipids and
lipid metabolites are still functionally uncharacterized or
completely unknown. In this current study, we attempted

Figure 4: Lipid metabolites whose levels were decreased with ACSS2 inhibition. (A–D) Among 27 lipid metabolites that

signiﬁcantly decreased by ACSS2 inhibitor in positive mode, four lipid species (A) CE(18:1), (B) CE(22:6), (C) TG(49:1), and (D)
TG(53:2) were identiﬁed. (E–G) Examples of lipid metabolites speciﬁcally responsive to ACSS2 inhibitor treatment only in T24R cells.
Three lipid species (E) 11.86_1000.92 in positive mode, (F) 12.22_369.35 in positive mode, and (G) 8.57_711.58/8.57_735.61 in negative
mode showed statistically signiﬁcant changes (p < 0.05 and fold-change >1.5) by ACSS2 inhibitor only in T24R cells. The lipid identiﬁers
denote retention (RT) time and m/z.
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Extraction

to extract and provide as much biological information as
possible on the lipid metabolites identiﬁed. In addition,
our study lacked further validation using independent and
targeted analyses. A ﬁnal major outstanding deﬁciency in
this study was lipidomics proﬁling using clinical samples,
which would have signiﬁcantly strengthened our ﬁndings.
In summary, we used an untargeted lipidomics
approach to depict a comprehensive picture of BC using
both cisplatin-sensitive and resistant cell lines. We have
conﬁdently proﬁled a diverse lipid signature of 1,037 and
827 lipids for these cell lines. Speciﬁcally, differential
lipid abundances were observed in molecular species that
are known to have signiﬁcant roles in regulating cancer
progression. Based on this lipidomic study, adjusting lipid
metabolism purposively may represent an optimal strategy
in overcoming cisplatin resistance and improving cancer
therapy. This study not only facilitates the development of
new drugs against cisplatin resistance, but also provides a
novel method in the clinical diagnosis of cisplatin-resistant
bladder cancer.

T24 cells were extracted as indicated in the
following protocols [50], which was slightly modiﬁed
from the earlier protocols [51]. The lipid extracts were
separated using methanol and MTBE, which can separate
lipids from proteins and other small polar hydrophilic
molecules in a way such that the lipids were found in the
top layer of a liquid-liquid separation, rather than in the
bottom layer. Therefore, decanting the top layer ensured
that the proteins or polar compounds did not contaminate
the lipid extracts. We optimized the choice of internal
standards and chromatographic conditions; e.g. by using
toluene in the reconstitution solvent mixture to ensure
that lipophilic components, like CE and TAGs, were
transferred to the UHPLC column during the injection
process.
Data acquisition
Data was acquired using the following
chromatographic parameters: Column, Waters Acquity UPLC
CSH C18 (100 mm length × 2.1 mm internal diameter;
1.7 μm particles); Mobile phase A, 60:40 acetonitrile:water
+ 10 mM ammonium formiate + 0.1% formic acid;
Mobile phase B, 90:10 v/v isopropanol:acetonitrile + 10
mM ammonium formate + 0.1% formic acid; Column
temperature: 65° C; Flow-rate: 0.6 mL/min; Injection
volume: 3 μL; Injection temperature: 4° C; Gradient: 0 min
15% (B), 0–2 min 30% (B), 2–2.5 min 48% (B), 2.5–11 min
82% (B), 11–11.5 min 99% (B), 11.5–12 min 99% (B), 12–
12.1 min 15% (B), 12.1–15 min 15% (B).
This chromatography method yielded excellent
retention and separation of lipid classes (PC, lysoPC, PE,
PS, TAG, ceramides) with narrow peak widths of 8–17 s.
In addition, we saw very good within-series retention time
reproducibility of better than 6 s absolute deviation. We
used automatic valve switching after each injection, which
was shown to reduce sample carryover for highly lipophilic
compounds, such as TAGs from 29% to 0.1%. The valve
switching occurred at 0.10, 11.60 and 13.00 minutes.
At 0.1 minutes, the sample has ﬂown through. Then at
11.60 minutes, the valve switching allows the mobile phase
(99% B) to ﬂow through the needle and ﬂush out any highly
lipophilic compounds. Finally, it switches at 13.00 minutes
to re-equilibrate the needle to initial conditions. 100%
isopropanol wash is used to wash the needle before every
injection (after sample has been picked up).
The following mass spectrometry parameters
were used: for positively charged lipids, such as PC,
lysoPC, PE, and PS, an Agilent 6530 QTOF mass
spectrometer was used with a resolution of R = 10,000;
for negatively charged lipids, such as free fatty acids
and phosphatidylinositols, an Agilent 6550 QTOF mass
spectrometer set at R = 20,000 was used.

MATERIALS AND METHODS
Cell culture and transfection
RT4, 5367, TCCSUP, and T24 BC cells were
obtained and cultured, according to instructions provided
by ATCC. Immortalized normal human bladder epithelial
cells, TRT-HU1, were maintained as described previously
[14]. Media was supplemented with 10% fetal bovine
serum, 2% glutamine and 1% antibiotics (Invitrogen,
Carlsbad, CA). Cells were maintained under a humidiﬁed
atmosphere of 5% CO2 at 37° C. The TRT-HU1 cell
line was constructed and extensively characterized in
previously published papers. These cells lines tested
negative for mycoplasma and all other infectious agents.

Cell survival assay
T24S and T24R cell lines were incubated with 10
mM cisplatin for 2 days. Cell survival was determined by
measuring cell viability using MTS reagents, according to
the company’s protocols (Promega Corporation, Madison,
WI).

Lipidomics by charged surface hybrid column
(CSH)-electrospray (ESI) quadrupole time of
ﬂight mass spectrometer (QTOF) MS/MS
Lipidomics and data analysis were conducted at the
NIH West Coast Metabolomics Center (UC Davis).
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Identiﬁcation and quantiﬁcation of lipids

retrieval, we used a high pH method. For counterstaining,
an Ultraview DAB Detection Kit (Ventana Medical
Systems) was used.

Raw data was processed through MS-DIAL [52].
First, peaks were detected and quantiﬁed for each sample. A
peak table including RT, m/z, and intensity was constructed
for each sample. Then, peak alignment across all samples
was performed in four steps: (1) a reference peak table was
constructed. The reference peak table started with one of
the sample tables. All peaks from other sample tables were
examined if they are in the reference table. If the peaks
are outside the RT and m/z tolerance of 0.1 min and 0.025
D, they were inserted to the reference peak table. (2) All
peak information including alignment ID, average RT,
average m/z and intensities of all samples were associated
to the reference peak table to generate a complete aligned
peak table. (3) The aligned peaks with missing intensity
information in all samples were ﬁltered out. (4) In order to
impute missing intensity values, MS-Dial searched a feature
with a local maximum intensity with the same RT and m/z
tolerance in step (1). When no feature was found to align in
a sample, MS-Dial ﬁlls zero to indicate that the abundance
of the peak was not measured.

Slide annotation and digitalized IHC analysis
The slides were annotated and characterized using
Leica Tissue IA 2.0 software (Copyright 2012 by SlidePath
Ltd.). For quality control measures, hematoxylin and eosin
(H&E) stained slides were used during the annotation. The
ACSS2 slide was viewed with its corresponding H&E
slide to ensure the annotation was done on the bladder
tumor epithelium only. Stromal and structural tissues
were cut off from annotation. A minimum number of cells
measured per slide were set up as 100,000 cells/core.
Following annotations, analysis was done using
the Leica Tissue IA 2.0 software. The Measure Stained
Cells Algorithm was selected. Color deﬁnition preferences
were deﬁned, and algorithm input parameters were
optimized by using several stained images of slides. The
optimized algorithm was used for the analysis of all slides.
Haematoxylin was set as the nuclear counter stain, and
3,3’Diaminobenzidine (DAB) was set as the nuclear,
cytoplasmic, and membrane marker.
Parameters in the software are based on a grayscale.
Zero is the minimum intensity (black), and 255 is
the maximum intensity (white). We set the threshold
range at 170 and 80 for positive and negative staining,
respectively. The max nuclear window size radius was
set to default and the nuclear area threshold was set to
0–500 mm2 (any nuclei or cells out of these range were
cut off). The minimum percentage of stained area in
order to be considered positive in the nucleus was set
to 20%. The threshold for cytoplasmic staining was set
at a higher range (160–22) because of the background
contrast of the cytoplasmic counterstain and the antibody
staining. In order for positive cytoplasmic staining
to be detected, the threshold had to be set higher since
the blue cytoplasmic staining was only slightly lighter
than the antibody staining. The minimum percentage of
stained area was set to 75%. After the annotation analysis,
data of the nuclear h-score, % of positive nuclei, % of
positive nuclear area, the cellular cytoplasmic h-score,
and % of positive cytoplasmic staining were collected
and visualized into box plots. Each annotated core had a
minimum threshold of 100,000 cells to be analyzed. Three
individual measurements were performed in a blinded
manner without any information of clinical data. After
computerized data analysis, positivity was collected from
data for the % of positive nuclei in tissue, which was used
for comparative graphing.

Normalization and identiﬁcation of differentially
expressed lipids
The normalization procedure was based on the sum
of all peak heights for all identiﬁed lipids in each sample
that were deﬁned as mTIC. The normalization factor for
a sample was calculated by dividing the average mTIC by
the mTIC of the sample being assessed. The intensities of
all the lipid species were then multiplied by the calculated
normalization factor. Differentially expressed lipids (DEL)
were identiﬁed based on a signiﬁcance test of P < 0.05 from
a two-sample t-test and if there was a fold change greater
than 1.5. The Q-value, an FDR adjusted p-value, was
computed for each p-value using the procedure introduced
by Storey, 2002 [53]. Principal component analysis (PCA)
was applied to summarize variations in the lipid proﬁles of
different cell lines and the effect of treatment with ACSS1
inhibitor. The normalized intensities were transformed
to a log scale with a base of 2. The missing values in a
lipid species were estimated as the minimum value of the
quantiﬁed values before PCA was applied. To cluster lipids
that shared similar intensity proﬁles across conditions,
hierarchical clustering was applied with Ward linkage and
Euclidean distance as a similarity measure.

IHC analysis using TMA
The tissue microarrays (TMA) were obtained from
a commercial resource (Biomax, BL802). They contain
80 cases in 80 cores. Sixty cores were bladder cancer
tissues, 10 cores were normal bladder tissues, and 10 cores
were normal adjacent to tumors. The antibody speciﬁc
to ACSS2 (D19C6) was purchased from Cell Signaling
Technology (Beverly, MA, United States). For the antigen
www.impactjournals.com/oncotarget

Measurement of lipid levels in cells
Cells (1.2 × 106/experimental group) were ﬁnely
harvested in phosphate buffered saline (PBS) on ice, and
total lipid levels were determined after lipid extraction
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using the Inﬁnity Cholesterol Liquid Stable Reagent
(Thermo Electron Corp., Waltham, MA).

5. Inazu M. Choline transporter-like proteins CTLs/SLC44
family as a novel molecular target for cancer therapy.
Biopharm Drug Dispos. 2014; 35:431–49. https://doi.
org/10.1002/bdd.1892.

Statistical analysis

6. Wenk MR. The emerging ﬁeld of lipidomics. Nat Rev Drug
Discov. 2005; 4:594–610. https://doi.org/10.1038/nrd1776.

The mean of more than three replicates was used as
the average. The p-values were calculated using a standard
unpaired Student’s t-test for simple comparisons and
p > 0.05 was considered statistically signiﬁcant.
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Prats N, Benitah SA. Loss of Dnmt3a and Dnmt3b does
not affect epidermal homeostasis but promotes squamous
transformation through PPAR-gamma. Elife. 2017; 6.
https://doi.org/10.7554/eLife.21697.
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